Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities
Labcorp (NYSE: LH) has announced a strategic collaboration with Roche to implement FDA-cleared VENTANA® DP 600 and DP 200 slide scanners for digital pathology. This initiative aims to transform traditional pathology by converting glass slides into high-resolution digital images, enabling remote viewing and analysis.
The collaboration comes as the U.S. faces a projected shortage of 5,700 pathologists by 2030. The digital pathology system will enhance diagnostic capabilities through improved access to expertise, streamlined workflows, and future AI integration. This builds upon Labcorp's existing relationship with Roche and extends across their Diagnostics and Biopharma Laboratory Services segments.
Labcorp (NYSE: LH) ha annunciato una collaborazione strategica con Roche per implementare i dispositivi VENTANA® DP 600 e DP 200 per la patologia digitale, già approvati dalla FDA. L'iniziativa intende trasformare la patologia tradizionale convertendo i vetrini di vetro in immagini digitali ad alta risoluzione, consentendo la visualizzazione e l'analisi da remoto. La collaborazione arriva mentre gli Stati Uniti stimano una carenza di 5.700 patologhi entro il 2030. Il sistema di patologia digitale migliorerà le capacità diagnostiche attraverso un migliore accesso all'expertise, flussi di lavoro semplificati e una futura integrazione dell'IA. Questo si aggiunge alla relazione già esistente tra Labcorp e Roche e si estende ai loro segmenti Diagnostics e Biopharma Laboratory Services.
Labcorp (NYSE: LH) ha anunciado una colaboración estratégica con Roche para implementar los escáneres de diapositivas VENTANA® DP 600 y DP 200 para patología digital, ya aprobados por la FDA. Esta iniciativa pretende transformar la patología tradicional convirtiendo las láminas de vidrio en imágenes digitales de alta resolución, permitiendo la visualización y el análisis a distancia.
La colaboración llega en un momento en que EE. UU. proyecta una escasez de 5.700 patólogos para 2030. El sistema de patología digital mejorará las capacidades diagnósticas mediante un mayor acceso a la experiencia, flujos de trabajo más eficientes y una futura integración de IA. Esto se suma a la relación existente de Labcorp con Roche y se extiende a través de sus segmentos Diagnostics y Biopharma Laboratory Services.
Labcorp (NYSE: LH)가 FDA 승인을 받은 VENTANA® DP 600 및 DP 200 슬라이드 스캐너를 디지털 병리학에 도입하기 위한 로슈와의 전략적 협업을 발표했습니다. 이 이니셔티브는 유리 슬라이드를 고해상도 디지털 이미지로 변환하여 원격 뷰잉과 분석을 가능하게 함으로써 전통적 병리학을 혁신하는 것을 목표로 합니다.
이번 협업은 2030년까지 미국에서 5,700명의 병리학자 부족이 예상된다는 상황에서 이루어집니다. 디지털 병리 시스템은 전문 지식에 대한 접근성 강화, 워크플로우 간소화, 향후 AI 통합을 통해 진단 역량을 향상시킬 것입니다. 이는 Labcorp와 Roche 간 기존 관계를 바탕으로 Diagnostics 및 Biopharma Laboratory Services 부문에 걸쳐 확장됩니다.
Labcorp (NYSE: LH) a annoncé une collaboration stratégique avec Roche pour mettre en œuvre les scanners de lames VENTANA® DP 600 et DP 200 approuvés par la FDA pour la pathologie numérique. Cette initiative vise à transformer la pathologie traditionnelle en convertissant les lames de verre en images numériques haute résolution, permettant une visualisation et une analyse à distance.
La collaboration intervient alors que les États-Unis prévoient une pénurie de 5 700 pathologistes d'ici 2030. Le système de pathologie numérique renforcera les capacités diagnostiques grâce à un meilleur accès à l'expertise, des flux de travail rationalisés et une future intégration de l'IA. Cela s'appuie sur la relation existante de Labcorp avec Roche et s'étend aux segments Diagnostics et Biopharma Laboratory Services.
Labcorp (NYSE: LH) hat eine strategische Zusammenarbeit mit Roche angekündigt, um die von der FDA freigegebenen VENTANA® DP 600 und DP 200 Slide-Scanner für die digitale Pathologie einzusetzen. Ziel ist es, die traditionelle Pathologie zu transformieren, indem Glaspräparate in hochauflösende digitale Bilder umgewandelt werden und so Fernansicht und -analyse ermöglichen.
Die Zusammenarbeit erfolgt zu dem Zeitpunkt, an dem in den USA eine prognostizierte Knappheit von 5.700 Pathologen bis 2030 erwartet wird. Das System der digitalen Pathologie wird Diagnostikfähigkeiten durch verbesserten Zugang zu Expertise, optimierte Arbeitsabläufe und eine zukünftige KI-Integration verbessern. Dies baut auf der bestehenden Beziehung von Labcorp zu Roche auf und erstreckt sich über die Segmente Diagnostics und Biopharma Laboratory Services.
Labcorp (NYSE: LH) أعلنت عن تعاون استراتيجي مع Roche لتنفيذ أجهزة VENTANA® DP 600 و DP 200 لشريحة العينة الارتكازية المعتمدة من FDA في علم الأمراض الرقمي. تهدف هذه المبادرة إلى تحويل علم الأمراض التقليدي من خلال تحويل شرائح الزجاج إلى صور رقمية عالية الدقة، مما يتيح العرض والتحليل عن بُعد.
يأتي ذلك في وقت تواجه فيه الولايات المتحدة نقصاً متوقعاً في 5,700 أخصائي علم أمراض بحلول 2030. سيعزز نظام علم الأمراض الرقمي القدرات التشخيصية من خلال تحسين الوصول إلى الخبرة، وتبسيط سير العمل، ودمج الذكاء الاصطناعي في المستقبل. وهذا يعزز العلاقة القائمة بين Labcorp و Roche ويمتد عبر قطاعات Diagnostics وBiopharma Laboratory Services.
Labcorp（NYSE: LH）宣布与 Roche 的战略合作，在数字病理学中实施经 FDA 认可的 VENTANA® DP 600 和 DP 200 slide scanners。这一举措旨在通过将玻璃切片转换为高分辨率的数字图像，实现远程查看与分析，从而改变传统病理学。
在美国预计到 2030 年将出现 5,700 名病理科医生短缺 的背景下，此次合作将通过改进对专业知识的获取、简化工作流程以及未来的 AI 集成，提升诊断能力。这是在 Labcorp 与 Roche 的现有关系基础上扩展，并覆盖其 Diagnostics 与 Biopharma Laboratory Services 部门。
- Addresses critical pathologist shortage through digital accessibility
- Enables remote consultations and faster specialist access
- Reduces operational costs by eliminating physical slide transport
- Creates foundation for future AI integration in pathology workflows
- Expands existing successful partnership with Roche
- Significant investment required for digital transformation
- Dependency on technology infrastructure and digital systems
Insights
Labcorp's digital pathology partnership with Roche addresses pathologist shortages while creating efficiency gains and AI integration opportunities.
This strategic collaboration between Labcorp and Roche represents a significant advancement in diagnostic technology implementation. By adopting Roche's FDA-cleared VENTANA® DP 600 and DP 200 slide scanners, Labcorp is addressing a critical industry challenge – the projected shortage of 5,700 pathologists by 2030 amid growing diagnostic demand from an aging population.
The digitization of pathology workflows offers multiple operational advantages. Converting glass slides to digital images enables remote viewing and analysis, eliminating physical transportation requirements. This solves several problems simultaneously: reducing costs, minimizing damage risks to irreplaceable samples, and enabling specialist consultations regardless of geographic location.
What makes this particularly valuable is the foundation it creates for artificial intelligence integration. The digital format will allow AI tools to eventually analyze slides, potentially improving diagnostic consistency and efficiency. This represents both near-term workflow improvements and longer-term technological positioning as AI diagnostics mature.
This isn't Labcorp's first foray into digital pathology – they've already implemented similar technology in their Oncology business and used digital pathology globally for clinical trials. This broader implementation suggests positive results from earlier adoptions and confidence in the technology's return on investment. The partnership leverages complementary strengths: Labcorp's diagnostic service expertise and Roche's digital pathology solutions, potentially creating synergies that benefit both operational efficiency and patient care outcomes.
Labcorp to leverage Roche's digital pathology technology to expand access, enhance efficiency and support AI integration across anatomic pathology services
"Labcorp is committed to advancing its diagnostic capabilities through the adoption of innovative technologies," said Marcia Eisenberg, Ph.D., Labcorp's chief scientific officer. "Integrating digital slide scanning into our pathology workflow will help improve accuracy, streamline operations and enable future AI-driven insights."
Labcorp's initiative comes at a critical time for the field of pathology. The
The digital pathology workflow converts glass slides into high-resolution digital images that can be instantly viewed using a conventional PC workstation (rather than a microscope) and analyzed and shared from any location, eliminating reliance on physical slides and enabling pathologists to operate across different sites.
Key Features and Benefits of Digital Pathology:
- Improved access to expertise: Enables remote sharing of digital slides, eliminating reliance on physical slides and enabling rapid consultations with specialists, regardless of location.
- Enhanced efficiency: Streamlines workflows by eliminating the need to handle, transport or retrieve physical slides.
- Reduced cost and risk: Digital storage eliminates transit costs and minimizes the risk of slide damage or loss of irreplaceable tissue samples.
- AI integration: Establishes a foundation for AI tools that can improve consistency, accuracy and efficiency in pathology workflows.
Labcorp's investment builds on the company's existing relationship with Roche and its digital pathology portfolio for the company's Oncology business.
"We look forward to expanding our collaboration with Labcorp to advance the digital transformation of their pathology labs," said Michael Rivers, life cycle leader for digital pathology at Roche Tissue Diagnostics. "This collaboration, which combines Labcorp's strength in diagnostic services with Roche's expertise in digital pathology solutions, holds the potential to create new opportunities for highly efficient, timely and effective patient care."
This latest collaboration builds on Labcorp's commitment to expanding digital capabilities and delivering innovative solutions across its Diagnostics and Biopharma Laboratory Services (BLS) business segments. Labcorp teams use digital pathology technology globally to support clinical trials, enabling more efficient data sharing, centralized review and faster decision-making.
To learn more about Labcorp's digital pathology capabilities, visit https://www.labcorp.com/disciplines/digital-pathology-and-artificial-intelligence-ai
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than
Note: Roche and third-party algorithms on Roche Digital Pathology Open Environment are for Research Use Only. Not for use in diagnostic procedures. Roche is dedicated to clinically deploying its Digital Pathology Solutions and is actively pursuing approval/clearance for our portfolio of products. Please review the product labeling for compliance before utilization.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements with respect to the expected utility and benefits to patients and customers of the expanded use of digital pathology technologies.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-announces-collaboration-with-roche-to-advance-digital-pathology-capabilities-302570699.html
SOURCE Labcorp
FAQ
What is the new collaboration between Labcorp (NYSE: LH) and Roche?
How will digital pathology help address the pathologist shortage?
What are the main benefits of Labcorp's digital pathology implementation?
How does digital pathology improve efficiency in Labcorp's operations?
What is the impact of this collaboration on Labcorp's clinical trials?
